Citations

Clear

959 citation(s) found for "Service, F J".

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
Mathias, Christopher J. , Low, Phillip A. , Hewitt, L. Arthur , Kaufmann, Horacio , Morillo, Carlos A. , Biaggioni, Italo, Biaggioni, Italo , Freeman, Roy L. , Kaufmann, Horacio , Morillo, Carlos

Mayo Clinic

Hypertension | October 28, 2014 | Volume: 65 | Issue: 1 | Pages: 101-107

10.1161/hypertensionaha.114.04035 | PMID 25350981 Get It

Abstract— We evaluated whether droxidopa, a prodrug converted to norepinephrine, is beneficial in the treatment of symptomatic neurogenic orthostatic hypotension, which results from failure to generate an appropriate norepinephrine response to postural challenge. Patients with symptomatic neurogenic orthostatic hypotension and Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa titration (100–600 mg, 3× daily). Responders then received an additional 7-day open-label treatment at their individualized dose. Patients were subsequently randomized to continue with droxidopa or withdraw to placebo for 14 days. We then assessed patient-reported scores on the Orthostatic Hypotension Questionnaire and blood pressure measurements. Mean worsening of Orthostatic Hypotension Questionnaire dizziness/lightheadedness score from randomization to end of study (the primary outcome; N=101) was 1.9±3.2 with placebo and 1.3±2.8 units with droxidopa ( P =0.509). Four of the other 5 Orthostatic Hypotension Questionnaire symptom scores and all 4 symptom-impact scores favored droxidopa, with statistical significance for the patient’s self-reported ability to perform activities requiring standing a short time ( P =0.033) and standing a long time ( P =0.028). Furthermore, a post hoc analysis of a predefined composite score of all symptoms (Orthostatic Hypotension Questionnaire composite) demonstrated a significant benefit for droxidopa ( P =0.013). There was no significant difference between groups for standing systolic blood pressure ( P =0.680). Droxidopa was well tolerated. In summary, this randomized withdrawal droxidopa study failed to meet its primary efficacy end point. Additional clinical trials are needed to confirm that droxidopa is beneficial in symptomatic neurogenic orthostatic hypotension, as suggested by the positive secondary outcomes of this trial. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00633880.
Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Peterlongo, Paolo , Chang-Claude, Jenny, Moysich, Kirsten B., Schmutzler, Rita K., Simard, Jacques , Soucy, Penny, Eeles, Rosalind A. , Easton, Douglas F. , Hamann, Ute, Wilkening, Stefan, Chen, Bowang , Rookus, Matti A. , Schmidt, Marjanka K. , Baan, Frederieke H. van der , Spurdle, Amanda B. , Walker, Logan C. , Lose, Felicity , Maia, Ana-Teresa , Montagna, Marco , Matricardi, Laura , Lubiński, Jan , Jakubowska, Anna , Gómez, E. , Olopade, Olufunmilayo I., Nathanson, Katherine L. , Rebbeck, Timothy R., Arun, Banu K., Karlan, Beth Y., Oršulić, Sandra , Lester, Jenny, Chung, Wendy K., Miron, Alex, Southey, Melissa C. , Goldgar, David E., Janavičius, Ramūnas , Dorfling, Cecilia M., Rensburg, Elizabeth J. van , Ding, Yuan Chun , Neuhausen, Susan L., Hansen, Thomas van Overeem , Gerdes, Anne‐Marie , Ejlertsen, Bent , Jønson, Lars, Osório, Ana , Martínez-Bouzas, Cristina, Benı́tez, Javier , Conway, Edye E., Blazer, Kathleen R. , Weitzel, Jeffrey N. , Manoukian, Siranoush , Peissel, Bernard , Zaffaroni, Daniela , Scuvera, Giulietta, Barile, Monica, Ficarazzi, Filomena , Mariette, Frédérique, Fortuzzi, Stefano , Viel, Alessandra , Giannini, Giuseppe , Papi, Laura , Martayan, Aline , Tibiletti, Maria Grazia , Radice, Paolo , Vratimos, Athanassios, Fostira, Florentia, Donaldson, Alan, Brewer, Carole, Foo, Claire, Evans, D. Gareth , Frost, Debra, Eccles, Diana , Brady, Angela, Adlard, Julian , Walker, Lisa, Izatt, Louise , Side, Lucy E., Rogers, Mark T., Porteous, Mary, Morrison, Patrick J., Platte, Radka, Davidson, Rosemarie, Hodgson, Shirley V. , Ellis, Steve, Cole, Trevor, EMBRACE, on behalf of, Claes, Kathleen , Maerken, Tom Van, Meindl, Alfons , Gehrig, Andrea, Sutter, Christian , Engel, Christoph , Niederacher, Dieter , Plendl, Hansjoerg, Kast, Karin, Rhiem, Kerstin, Ditsch, Nina , Varon-Mateeva, Raymonda, Wappenschmidt, Barbara , Wang-Gohrke, Shan, Paillerets, Brigitte Bressac–de , Buecher, Bruno , Delnatte, Capucine, Houdayer, Claude , Coupier, Isabelle, Barjhoux, Laure, Venat‐Bouvet, Laurence , Boutry‐Kryza, Nadia, Sinilnikova, Olga M., Caron, Olivier , Mazoyer, Sylvie , Belotti, Muriel, Collaborators, on behalf of GEMO Study, Piedmonte, Marion, Friedländer, Michael , Rodriguez, Gustavo C., Copeland, Larry J. , Hoya, Miguel de la , Segura, Pedro Pérez, Nevanlinna, Heli , Aittomäki, Kristiina, Os, Theo A.M. van, Meijers-Heijboer, Hanne E.J., Hout, Annemarie H. van der, Hoogerbrugge, Nicoline, Ausems, Margreet G.E.M. , Doorn, Helena C. van , Collée, Margriet , HEBON, on behalf of, Oláh, Edith , Dı́ez, Orland , Blanco, Ignacio , Lázaro, Conxi , Brunet, Joan , Feliubadaló, Lídia , Cybulski, Cezary, Durda, Katarzyna, Jaworska–Bieniek, Katarzyna, Sukiennicki, Grzegorz, Arason, Aðalgeir , Chiquette, Jocelyne , Teixeira, Manuel R. , Olswold, Curtis, Lindor, Noralane M. , Offit, Kenneth, Corines, Marina, Jacobs, Lauren , Robson, Mark E. , Zhang, Liying , Vijai, Joseph , Berger, Andreas, Singer, Christian F., Rappaport, Christine , Kaulich, Daphne Geschwantler, Pfeiler, Georg , Tea, Muy-Kheng M., Phelan, Catherine M., Greene, Mark H. , Mai, Phuong L., Rennert, Gad , Mulligan, Anna Marie , Glendon, Gord , Tchatchou, Sandrine, Andrulis, Irene L., Bojesen, Anders , Pedersen, Inge Søkilde , Thomassen, Mads , Jensen, Uffe Birk , Laitman, Yael , Rantala, Johanna, Wachenfeldt, Anna von , Ehrencrona, Hans , Askmalm, Marie Stenmark, Borg, Åke , Kuchenbaecker, Karoline B., McGuffog, Lesley, Barrowdale, Daniel , Healey, Sue, Lee, Andrew , Chenevix‐Trench, Georgia , Investigators, on behalf of KConFab, Antoniou, Antonis C. , Friedman, Eitan , Durocher, Francine , Olopade, Olufunmilayo I. , Hoogerbrugge, Nicoline , Thorne, Heather , Stenmark‐Askmalm, Marie , Wang, Xianshu , Chang‐Claude, Jenny, Moysich, Kirsten B. , Rudolph, Anja , Nussbaum, Robert L. , Domchek, Susan M. , Arun, Banu , By, Karlan, Chung, Wendy K. , Buys, Saundra S. , Garber, Judy E. , Cook, Jackie A , Tischkowitz, Marc D. , Barwell, Julian , Kennedy, Michael John , Ellis, Steve, EMBRACE, on behalf of, Godwin, Andrew K. , Meindl, Alfons , Steinemann, Doris , Arnold, Norbert , Wang-Gohrke, Shan, Stoppa‐Lyonnet, Dominique , Damiola, Francesca , Golmard, Lisa , Pujol, Pascal , Collaborators, on behalf of GEMO Study, Meijers‐Heijboer, Hanne , Vreeswijk, Maaike P.G. , Hoogerbrugge, Nicoline, HEBON, on behalf of, Gronwald, Jacek , Couch, Fergus J. , Szabo, Csilla I. , Singer, Christian F , Mai, Phuong L., Toland, Amanda Ewart , Pharoah, Paul D.P. , Investigators, on behalf of KConFab, Nevanlinna, H , Peterlongo, Paolo , Rennert, Gad , Spurdle, Amanda B , Teixeira, Manuel R , van Rensburg, Elizabeth J , Eccles, Diana , Moysich, Kirsten , de la Hoya, Miguel , Diez, Orland , Radice, Paolo , Weitzel, Jeffrey N , Claes, Kathleen B M , Adlard, Julian , Brunet, Joan , Eeles, Rosalind A , Ehrencrona, Hans , Evans, D Gareth , Joseph, Vijai , Matricardi, Laura , Olopade, Olufunmilayo I , Southey, Melissa C , Jakubowska, Anna , Schmidt, Marjanka K , Nathanson, Katherine L , Friedlander, Michael , Arason, Adalgeir , Barrowdale, Daniel , Benitez, Javier , Engel, Christoph , Lazaro, Conxi , Montagna, Marco , Robson, Mark , Viel, Alessandra , Simard, Jacques , Chenevix-Trench, Georgia , Feliubadaló, Lidia , Gómez-García, Encarna B , Hansen, Thomas van Overeem , Manoukian, Siranoush , Lubinski, Jan , Rhiem, Kerstin

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 22, 2014 | Volume: 24 | Issue: 1 | Pages: 308-316

10.1158/1055-9965.epi-14-0532 | PMID 25336561 Get It

Abstract Background:BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. Cancer Epidemiol Biomarkers Prev; 24(1); 308–16. ©2014 AACR.
The EADC‐ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity
Frisoni, Giovanni B. , Jack, Clifford R. , Bocchetta, Martina , Frederiksen, Kristian Steen , Liu, Yawu , Preboske, Gregory M., Swihart, Tim, Blair, Melanie , Cavedo, Enrica , Grothe, Michel J. , Lanfredi, Mariangela , Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis , Ward, Chadwich, Apostolova, Liana G. , Ganzola, Rossana , Barkhof, Frederik , Bartzokis, George, DeCarli, Charles , Csernansky, John G., deToledo‐Morrell, Leyla, Geerlings, Mirjam I. , Lehéricy, Stéphane , O’Brien, John T. , Silbert, Lisa C. , Scheltens, Philip , Waldemar, Gunhild, Fellgiebel, Andreas , Barnes, Josephine , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pruessner, Jens C. , Watson, Craig, Leon, Mony J. de , Pantel, Johannes, Ferrari, Clarissa , Bosco, Paolo , Pasqualetti, Patrizio , Duchesne, Simon , Duvernoy, Henri M., Boccardi, Marina , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging, Albert, Marilyn S. , Bennet, David, Camicioli, Richard , Collins, D. Louis , Dubois, Bruno , Hampel, Harald , denHeijer, Tom, Hock, Christofer, Jagust, William J. , Launer, Leonore J., Maller, Jerome J. , Mueller, S. G., Sachdev, Perminder S. , Simmons, Andy, Visser, Peter‐Jelle, Wahlund, Lars‐Olof , Weiner, Michael W. , Winblad, Bengt , Boccardi, Marina , Frisoni, Giovanni B. , DeCarli, Charles , Preboske, Gregory, Bauer, Corinna M. , Wolf, Dominik Georg Friedrich , Kaye, Jeffrey , Killiany, Ronald , Matsuda, Hiroshi , O'Brien, John Tiernan , Soininen, Hilkka S. , Teipel, Stefan Johannes , Waldemar, Gunhild , Firbank, Michael John , Wang, Lei , Wolf, Henrike , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging, Thompson, Paul M. , Jack, Clifford R , Sachdev, Perminder S , Barkhof, Frederik , Scheltens, Philip , Wahlund, Lars-Olof , Grothe, Michel J , Bocchetta, Martina , Stoub, Travis

Mayo Clinic

Alzheimer's & Dementia | September 27, 2014 | Volume: 11 | Issue: 2 | Pages: 111-125

10.1016/j.jalz.2014.05.1756 | PMID 25267715 Get It

Abstract Background An international Delphi panel has defined a harmonized protocol (HarP) for the manual segmentation of the hippocampus on MR. The aim of this study is to study the concurrent validity of the HarP toward local protocols, and its major sources of variance. Methods Fourteen tracers segmented 10 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases scanned at 1.5 T and 3T following local protocols, qualified for segmentation based on the HarP through a standard web‐platform and resegmented following the HarP. The five most accurate tracers followed the HarP to segment 15 ADNI cases acquired at three time points on both 1.5 T and 3T. Results The agreement among tracers was relatively low with the local protocols (absolute left/right ICC 0.44/0.43) and much higher with the HarP (absolute left/right ICC 0.88/0.89). On the larger set of 15 cases, the HarP agreement within (left/right ICC range: 0.94/0.95 to 0.99/0.99) and among tracers (left/right ICC range: 0.89/0.90) was very high. The volume variance due to different tracers was 0.9% of the total, comparing favorably to variance due to scanner manufacturer (1.2), atrophy rates (3.5), hemispheric asymmetry (3.7), field strength (4.4), and significantly smaller than the variance due to atrophy (33.5%, P < .001), and physiological variability (49.2%, P < .001). Conclusions The HarP has high measurement stability compared with local segmentation protocols, and good reproducibility within and among human tracers. Hippocampi segmented with the HarP can be used as a reference for the qualification of human tracers and automated segmentation algorithms.
Harmonized benchmark labels of the hippocampus on magnetic resonance: The EADC‐ADNI project
Bocchetta, Martina , Boccardi, Marina , Ganzola, Rossana , Apostolova, Liana G. , Preboske, Gregory M., Ferrari, Clarissa , Pasqualetti, Patrizio , Robitaille, Nicolas , Duchesne, Simon , Jack, Clifford R. , Frisoni, Giovanni B. , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging, Bartzokis, George, deToledo‐Morrell, Leyla, Fellgiebel, Andreas , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pruessner, Jens C. , Watson, Craig, Boccardi, Marina , Frisoni, Giovanni B. , Preboske, Gregory, Wolf, Dominik Georg Friedrich , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , Firbank, Michael John , Killiany, Ronald , Soininen, Hilkka S. , Wang, Lei , Wolf, Henrike , Jack, Clifford R , Bocchetta, Martina

Mayo Clinic

Alzheimer's & Dementia | September 13, 2014 | Volume: 11 | Issue: 2 | Pages: 151

10.1016/j.jalz.2013.12.019 | PMID 25223727 Get It

AbstractBackgroundA globally harmonized protocol (HarP) for manual hippocampal segmentation based on magnetic resonance has been recently developed by a task force from European Alzheimer's Disease Consortium (EADC) and Alzheimer's Disease Neuroimaging Initiative (ADNI). Our aim was to produce benchmark labels based on the HarP for manual segmentation.MethodsFive experts of manual hippocampal segmentation underwent specific training on the HarP and segmented 40 right and left hippocampi from 10 ADNI subjects on both 1.5 T and 3 T scans. An independent expert visually checked segmentations for compliance with the HarP. Descriptive measures of agreement between tracers were intraclass correlation coefficients (ICCs) of crude volumes and similarity coefficients of three‐dimensional volumes.ResultsTwo hundred labels have been provided for the 20 magnetic resonance images. Intra‐ and interrater ICCs were >0.94, and mean similarity coefficients were 1.5 T, 0.73 (95% confidence interval [CI], 0.71–0.75); 3 T, 0.75 (95% CI, 0.74–0.76).ConclusionCertified benchmark labels have been produced based on the HarP to be used for tracers' training and qualification.
Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Üstün, Celalettin , Reiter, Andreas , Scott, Bart L. , Nakamura, Ryotaro , Damaj, Gandhi , Kreil, Sebastian, Shanley, Ryan , Baurmann, H., Doubek, Michael , Hsu, Jack W., Tholouli, Eleni , Gromke, Tanja , Godley, Lucy A. , Pagano, Livio , Gilman, Andrew L. , Wagner, Eva , Shwayder, Tor , Papadopoulos, Esperanza B. , Böhm, Alexandra, Vercellotti, Gregory M. , Lint, Maria Teresa Van, Rabitsch, Werner , Pullarkat, Vinod , Legrand, Faézeh, Yakoub‐Agha, Ibrahim , Saber, Wael , Barrett, J. Carl, Hermine, Olivier , Hägglund, Hans , Sperr, Wolfgang R. , Alyea, Edwin P. , Deeg, H. Joachim , Weisdorf, Daniel J. , Akin, Cem , Valent, Peter , Shore, Tsiporah, Baurmann, Herrad, Stuart, Robert, Gruhn, Bernd, Gilman, Andrew, Wagner, Eva Maria, Bornhäuser, Martin, Vercellotti, Gregory, Van Lint, Maria Teresa, Schmid, Christoph, Yakoub-Agha, Ibrahim, Barrett, John , Popat, Uday, Devine, Steven, Weisdorf, Daniel, Hogan, William J. , Perales, Miguel‐Angel , Shore, Tsiporah B. , Stuart, Robert K. , Gruhn, Bernd , Bornhäuser, Martin , Schmid, Christoph , Popat, Uday R , Devine, Steven M. , Weisdorf, Dan , Sperr, Wolfgang , Valent, Peter , Yakoub-Agha, Ibrahim , Hermine, Olivier , Akin, Cem , Godley, Lucy A

Mayo Clinic

Journal of Clinical Oncology | August 26, 2014 | Volume: 32 | Issue: 29 | Pages: 3264-3274

10.1200/jco.2014.55.2018 | PMID 25154823 Get It

PurposeAdvanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown.Patients and MethodsIn a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1), or unknown (n = 3). Thirty-six patients received myeloablative conditioning (MAC), and 21 patients received reduced-intensity conditioning (RIC).ResultsResponses in SM were observed in 40 patients (70%), with complete remission in 16 patients (28%). Twelve patients (21%) had stable disease, and five patients (9%) had primary refractory disease. Overall survival (OS) at 3 years was 57% for all patients, 74% for patients with SM-AHNMD, 43% for those with ASM, and 17% for those with MCL. The strongest risk factor for poor OS was MCL. Survival was also lower in patients receiving RIC compared with MAC and in patients having progression compared with patients having stable disease or response.ConclusionAlloHCT was associated with long-term survival in patients with advanced SM. Although alloHCT may be considered as a viable and potentially curative therapeutic option for advanced SM in the meantime, given that this is a retrospective analysis with no control group, the definitive role of alloHCT will need to be determined by a prospective trial.
Delphi definition of the EADC‐ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance
Boccardi, Marina , Bocchetta, Martina , Apostolova, Liana G. , Barnes, Josephine , Bartzokis, George, Corbetta, Gabriele , DeCarli, Charles , deToledo‐Morrell, Leyla, Ganzola, Rossana , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pasqualetti, Patrizio , Pruessner, Jens C. , Redolfi, Alberto , Robitaille, Nicolas , Tolomeo, Daniele , Watson, Craig, Duvernoy, Henri M., Duchesne, Simon , Jack, Clifford R. , Frisoni, Giovanni B. , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Boccardi, Marina , Frisoni, Giovanni B. , DeCarli, Charles , Firbank, Michael John , Killiany, Ronald , Soininen, Hilkka S. , Wang, Lei , Wolf, Henrike , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Jack, Clifford R , Bocchetta, Martina

Mayo Clinic

Alzheimer's & Dementia | August 15, 2014 | Volume: 11 | Issue: 2 | Pages: 126-138

10.1016/j.jalz.2014.02.009 | PMID 25130658 Get It

Abstract Background This study aimed to have international experts converge on a harmonized definition of whole hippocampus boundaries and segmentation procedures, to define standard operating procedures for magnetic resonance (MR)‐based manual hippocampal segmentation. Methods The panel received a questionnaire regarding whole hippocampus boundaries and segmentation procedures. Quantitative information was supplied to allow evidence‐based answers. A recursive and anonymous Delphi procedure was used to achieve convergence. Significance of agreement among panelists was assessed by exact probability on Fisher's and binomial tests. Results Agreement was significant on the inclusion of alveus/fimbria ( P = .021), whole hippocampal tail ( P = .013), medial border of the body according to visible morphology ( P = .0006), and on this combined set of features ( P = .001). This definition captures 100% of hippocampal tissue, 100% of Alzheimer’s disease‐related atrophy, and demonstrated good reliability on preliminary intrarater (0.98) and inter‐rater (0.94) estimates. Discussion Consensus was achieved among international experts with respect to hippocampal segmentation using MR resulting in a harmonized segmentation protocol.
Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors.
Jiang, Ping , Ramanathan, Ramesh K., Infante, Jeffrey R., Bessudo, Alberto, LoRusso, Patricia , Sugarman, Barry J., Carson, Deborah Stier, Selvam, Paneer, Zhu, Joy, Korn, Ronald L. , Shepard, H. Michael , Frost, Gregory I., Infante, Jon , Maneval, Daniel C. , Borad, Mitesh J. , Printz, Marie A. , Thompson, Curtis B. , Frost, Gregory I., Infante, Jon

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 3375-3375

10.1158/1538-7445.am2013-3375 Get It

Abstract Enzymatic degradation of hyaluronan (HA), a key component of the extracellular matrix (ECM), can enhance tumor perfusion, improve delivery of chemotherapeutics, and enhance the effects of anti-tumor agents. HA accumulation has been correlated with local invasion, the presence of distal metastasis, higher tumor grade, and poorer overall survival. PEGPH20, a pegylated form of recombinant human hyaluronidase PH20, is an investigational therapeutic agent under clinical development for the treatment of patients with solid tumors that may accumulate HA. Preclinical studies have demonstrated that sustained HA removal, accomplished with PEGPH20, inhibits tumor growth and enhances chemotherapeutic activity in HA-rich xenografts and genetically engineered mouse tumor models. Twenty-six patients with advanced solid tumors were enrolled in a Phase 1 multi-center trial. Patients received weekly or twice weekly doses of IV PEGPH20 (0.5 - 5 μg/kg) for the first 4-week cycle, followed by once-weekly dosing for the subsequent 4-week cycles. Serial blood samples were drawn from each patient, and plasma concentrations were measured by an ultrasensitive hyaluronidase activity assay to assess PEGPH20 pharmacokinetics (PK). Plasma levels of HA catabolites were measured using a quantitative HPLC method to characterize PEGPH20 pharmacodynamics (PD). Other measures of PD activity were evaluated in selected patients, including DCE-MRI, DW-MRI, 18FDG-PET, textural analysis on CT, and histochemical staining of HA in tumor biopsies collected both before and after PEGPH20 treatment. Peak plasma PEGPH20 concentrations increased with dose, and plasma pharmacokinetics (PK) were well described by a linear PK model. Pre-treatment plasma HA levels were typically &lt;1 μg/mL and increased in a dose-dependent fashion after PEGPH20 treatment. Increased plasma HA corresponded with decreased HA staining in patients with available tumor biopsies. DCE-MRI analysis indicated early (24-48 hr) and rapid increase in tumor perfusion compared to baseline in 4 patients with serial MRI assessments. Pharmacodynamic activity was also demonstrated when pre-treatment 18FDG-PET scans were compared with images collected at scheduled times after PEGPH20 dosing. Reduction in FDG uptake exceeding 25% was demonstrated in 3 of 4 patients after one cycle of treatment, consistent with a partial metabolic response. These data are consistent with the mechanism of action reported in preclinical models, and results support continued evaluation of PEGPH20 in combination with anti-tumor agents via modification of the ECM. Citation Format: Ping Jiang, Daniel C. Maneval, Ramesh K. Ramanathan, Jeffrey R. Infante, Mitesh Borad, Alberto Bessudo, Patricia LoRusso, Barry J. Sugarman, Deborah Carson, Marie A. Printz, Curtis B. Thompson, Paneer Selvam, Joy Zhu, Ronald Korn, H Michael Shepard, Gregory I. Frost. Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3375. doi:10.1158/1538-7445.AM2013-3375
Radiosurgery is an Effective Treatment for Recurrent Esthesioneuroblastoma: A Multicenter Study
Link, Michael J. , Sheehan, Jason P. , Xu, Zhiyuan , Mathieu, David , Kano, Hideyuki , Lunsford, L. Dade , Van Gompel, Jamie J, Gompel, Jamie J. Van , Mathieu, David

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 4, 2014 | Volume: 75 | Issue: 06 | Pages: 409-414

10.1055/s-0034-1378151 | PMID 25452899 Get It

AQP4 autoantibody assay performance in clinical laboratory service
Fryer, J.P. , Lennon, Vanda A. , Pittock, Sean J. , Jenkins, Sarah M. , Fallier‐Becker, Petra, Clardy, Stacey , Horta, Erika , Jedynak, E.A., Lucchinetti, Claudia F. , Shuster, Elizabeth A., Weinshenker, Brian G. , Wingerchuk, Dean M. , McKeon, Andrew , Pittock, S J , Weinshenker, Brian G , McKeon, Andrew , Clardy, Stacey L

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | May 23, 2014 | Volume: 1 | Issue: 1 | Pages: No page available

10.1212/nxi.0000000000000011 | PMID 25340055 Get It